EVOTF: AI 评分 45/100 — AI 分析 (4月 2026)

Evotec SE is a drug discovery and development partner for the pharmaceutical and biotechnology industry. The company focuses on developing pharmaceutical products across various therapeutic areas and collaborates with major pharmaceutical companies.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Evotec SE, a global drug discovery and development partner, collaborates with pharmaceutical and biotechnology companies across diverse therapeutic areas, including diabetes, oncology, and immunology. Headquartered in Hamburg, Germany, Evotec leverages its research expertise and strategic partnerships to advance pharmaceutical innovation, operating in a competitive landscape with companies like BIOGY and CHIZF.

EVOTF是做什么的？

Evotec SE, established in 1993 and headquartered in Hamburg, Germany, operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Originally incorporated as Evotec AG, the company rebranded as Evotec SE in April 2019. Evotec's core business revolves around providing research services and developing pharmaceutical products across a broad spectrum of therapeutic areas. These areas include diabetes and its complications, fibrosis, infectious diseases, central nervous system (CNS) disorders, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. Evotec fosters strategic alliances with leading pharmaceutical companies, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, and Pfizer Inc., among others. These collaborations enable Evotec to leverage its research capabilities and contribute to the development of novel therapies. The company's extensive portfolio of partnerships underscores its position as a key player in the drug discovery and development ecosystem. Evotec's global reach extends to various regions, supporting pharmaceutical innovation on an international scale. With a focus on innovation and collaboration, Evotec continues to advance the development of new treatments for a wide range of diseases.

EVOTF的投资论点是什么？

Evotec SE presents a mixed investment case. While the company operates in a growing drug discovery and development market and has established partnerships with major pharmaceutical companies, its negative profit margin of -21.0% raises concerns about its financial performance. The company's collaborations with industry giants like Bayer and Pfizer provide revenue streams and validation of its research capabilities. However, the company's P/E ratio of -4.87 indicates it is not currently profitable. Upcoming catalysts include potential milestones from ongoing collaborations and advancements in its therapeutic programs. Investors should carefully weigh the growth potential against the current financial challenges.

EVOTF在哪个行业运营？

Evotec SE operates within the drug manufacturing industry, specifically focusing on specialty and generic drugs. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. The global pharmaceutical market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing prevalence of chronic diseases. Evotec competes with companies like BIOGY, CHIZF, and CMOPF, all vying for market share in drug discovery and development. The company's success depends on its ability to innovate, secure partnerships, and navigate the complex regulatory landscape.

Drug Manufacturers - Specialty & Generic

Healthcare

EVOTF有哪些增长机遇？

Expansion of Strategic Partnerships: Evotec can expand its network of strategic partnerships with pharmaceutical and biotechnology companies. By forging new collaborations, Evotec can access additional funding, diversify its project portfolio, and leverage the expertise of its partners. The global market for pharmaceutical collaborations is projected to reach billions of dollars, presenting a significant opportunity for Evotec to drive revenue growth and expand its market presence. Timeline: Ongoing.
Advancement of Proprietary Drug Development Programs: Evotec can accelerate the development of its proprietary drug development programs. By investing in research and clinical trials, Evotec can bring novel therapies to market and generate substantial revenue streams. The global market for new drug approvals is projected to grow significantly, driven by unmet medical needs and technological advancements. Timeline: Ongoing.
Geographic Expansion into Emerging Markets: Evotec can expand its geographic presence into emerging markets, such as Asia and Latin America. These markets offer significant growth opportunities due to their large populations, increasing healthcare spending, and unmet medical needs. By establishing operations in these regions, Evotec can tap into new revenue streams and diversify its geographic footprint. Timeline: 2-3 years.
Leveraging Artificial Intelligence and Machine Learning: Evotec can leverage artificial intelligence (AI) and machine learning (ML) technologies to accelerate drug discovery and development. By using AI and ML, Evotec can identify promising drug candidates, optimize clinical trial designs, and improve the efficiency of its research processes. The global market for AI in drug discovery is projected to grow substantially, presenting a significant opportunity for Evotec to enhance its competitive advantage. Timeline: Ongoing.
Focus on Personalized Medicine: Evotec can focus on developing personalized medicine solutions that are tailored to individual patients. By using genetic and other patient-specific information, Evotec can develop more effective and targeted therapies. The global market for personalized medicine is projected to grow rapidly, driven by advancements in genomics and diagnostics. Timeline: 3-5 years.

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry.
The company has collaboration agreements with major pharmaceutical companies, including Bayer AG and Pfizer Inc.
Evotec SE develops pharmaceutical products in various therapeutic areas, such as diabetes, oncology, and immunology.
The company's market capitalization is $0.93 billion.
Evotec SE has a negative profit margin of -21.0%.

EVOTF提供哪些产品和服务？

Provides drug discovery services to pharmaceutical and biotechnology companies.
Develops pharmaceutical products in various therapeutic areas.
Conducts research and development activities.
Engages in strategic collaborations with industry partners.
Offers integrated drug discovery solutions.
Focuses on therapeutic areas like diabetes, oncology, and immunology.
Utilizes advanced technologies for drug discovery.

EVOTF如何赚钱？

Generates revenue through research and development collaborations with pharmaceutical and biotechnology companies.
Receives milestone payments and royalties from partnered drug development programs.
Provides fee-for-service research and development services.
Develops and out-licenses proprietary drug candidates.

Pharmaceutical companies.
Biotechnology companies.
Academic research institutions.
Government research agencies.

Established partnerships with major pharmaceutical companies.
Expertise in drug discovery and development across various therapeutic areas.
Proprietary technologies and platforms for drug discovery.
Strong reputation and track record in the industry.

什么因素可能推动EVOTF股价上涨？

Upcoming: Potential milestone payments from existing collaboration agreements.
Ongoing: Advancements in proprietary drug development programs.
Ongoing: Expansion of strategic partnerships with pharmaceutical companies.
Upcoming: Positive clinical trial results for key drug candidates.

EVOTF的主要风险是什么？

Potential: Failure to achieve milestones in collaboration agreements.
Ongoing: Competition from other drug discovery and development companies.
Potential: Patent expirations and generic drug competition.
Ongoing: Regulatory risks and changes in healthcare policies.
Potential: Negative clinical trial results for key drug candidates.

EVOTF的核心优势是什么？

Strong partnerships with major pharmaceutical companies.
Diverse portfolio of drug development programs.
Expertise in multiple therapeutic areas.
Established presence in the drug discovery and development market.

EVOTF的劣势是什么？

Negative profit margin.
Dependence on collaboration agreements for revenue.
Exposure to regulatory risks.
Competition from other drug discovery and development companies.

EVOTF有哪些机遇？

Expansion into emerging markets.
Advancement of proprietary drug development programs.
Leveraging artificial intelligence and machine learning.
Focus on personalized medicine.

EVOTF面临哪些威胁？

Patent expirations.
Competition from generic drugs.
Changes in regulatory requirements.
Economic downturns.

EVOTF的竞争对手是谁？

Biogen Inc. — Focuses on neurological diseases. — (BIOGY)
Chiesi Farmaceutici S.p.A. — Specializes in respiratory and specialty care. — (CHIZF)
Cmo S.A. — Contract Manufacturing Organization — (CMOPF)
Genmab A/S — Develops antibody therapeutics for cancer. — (GNMLF)
Kyowa Kirin Co., Ltd. — Focuses on nephrology, oncology, and immunology. — (KSPHF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Christian Wojczewski
Headquarters: Hamburg, DE
Employees: 4,766
Founded: 2009

AI Insight

AI analysis pending for EVOTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Evotec SE do?

Evotec SE operates as a drug discovery and development partner, providing services and expertise to pharmaceutical and biotechnology companies worldwide. The company focuses on identifying and developing new drug candidates across various therapeutic areas, including diabetes, oncology, and immunology. Evotec collaborates with industry partners to advance these drug candidates through preclinical and clinical development, with the goal of bringing innovative therapies to market. The company's business model revolves around generating revenue through research collaborations, milestone payments, and royalties from partnered drug programs.

What do analysts say about EVOTF stock?

Analyst opinions on EVOTF stock are currently mixed, reflecting the company's unique position as a drug discovery and development partner. Key valuation metrics, such as the negative P/E ratio, indicate that the company is not currently profitable. However, analysts recognize Evotec's growth potential, driven by its strategic partnerships and advancements in its drug development programs. Analyst consensus suggests that Evotec's long-term success depends on its ability to secure new collaborations, achieve milestones in existing partnerships, and navigate the complex regulatory landscape. Investors should conduct their own research and consider their risk tolerance before investing in EVOTF stock.

What are the main risks for EVOTF?

Evotec SE faces several key risks inherent to the pharmaceutical industry and its specific business model. One significant risk is the dependence on collaboration agreements for revenue, as failure to secure or maintain these partnerships could negatively impact the company's financial performance. Additionally, Evotec is exposed to regulatory risks, including changes in healthcare policies and drug approval processes. Competition from other drug discovery and development companies also poses a threat. Furthermore, the company's drug development programs are subject to clinical trial risks, such as negative results or delays, which could impact the value of its pipeline.